Clearmind Medicine Moves to Acquire Wireless EV Charging Company
The biotech firm plans a $2.5-million investment for a 51 percent stake in an unnamed wireless charging technology developer.
Clearmind Medicine, a clinical-stage biotech company focused on neuroplastogen-derived therapeutics, has signed a non-binding Letter of Intent to acquire a majority stake in a wireless EV charging technology firm.
What Happened
The target company provides wireless charging solutions for automated parking systems and autonomous mobile platforms. According to Clearmind, the unnamed firm's proprietary technology enables charging at speeds up to 10 kW and features smart communication and dynamic energy management designed to integrate with robotic parking systems. Clearmind will pay $2.5 million for a 51 percent stake and extend an additional $1.5 million loan to the company.
Why It Matters
Wireless EV charging remains a niche but growing segment, particularly for autonomous vehicles and automated infrastructure where physical cable connections are impractical. The technology's integration with robotic parking systems could appeal to commercial fleet operators and urban developers seeking hands-free charging solutions. Clearmind's entry into this space marks an unusual diversification from its core biotech operations.
The Bottom Line
The non-binding LOI means the acquisition has not yet been finalized. If completed, it would represent a significant expansion beyond Clearmind's therapeutic focus and add 10 kW wireless charging technology to an emerging market segment serving automated parking and autonomous platforms.
